Cepetor 1 mg/ml

Cepetor 1 mg/ml is a solution for injection for dogs and cats to be used as sedation or premedication for general anaesthesia. Cepetor 1 mg/ml belongs to the veterinary medicinal products that may only be administered by veterinarians (UDD).

Cepetor 1 mg/ml has registration number NL 10457.



Dogs and cats:

  • Sedation to facilitate manageability. Premedication for general anesthesia.


  • In combination with ketamine: for general anesthesia in minor surgical procedures of short duration.


Dogs and cats:

Do not use in animals with:

  • Severe cardiovascular or respiratory disease or impaired hepatic or renal function
  • Mechanical obstructions of the gastrointestinal tract (torsio ventriculi, incarcerations, esophageal obstruction)
  • Pregnancy, Diabetes Mellitus
  • Shock, emaciation or severe weakness

Do not use at the same time as sympathomimetic amines.

Do not use in case of known hypersensitivity to the active substance or to any of the excipients.

Do not use in animals with eye problems where an increase in intraocular pressure is harmful.


Cepetor 1 mg/ml is a solution for injection.


Intramuscular or intravenous injection.

  • For sedation, the product should be administered at 750 µg medetomidine hydrochloride i.v. or 1000 µg medetomidine hydrochloride i.m. per square meter of body surface area. Use the table below to determine the correct dose based on body weight: The maximum effect is reached within 15-20 minutes. Clinical effect is dose dependent and lasts between 30 and 180 minutes. See the package leaflet for a table with Cepetor doses by kg body weight.
  • For premedication: 10 – 40 µg medetomidine hydrochloride per kg body weight, corresponding to 0.1 – 0.4 ml per 10 kg body weight. The exact dose will depend on the combination of drugs used and the dose(s) of the other drug(s). Furthermore, the dose should be adjusted according to the type of surgery, the duration of the procedure and the temperament and weight of the patient. Medetomidine premedication significantly reduces the dose of the induction agent required and decreases the amount of volatile anesthetic required for maintenance of anaesthesia. All anesthetics used for induction or maintenance of anesthesia should be administered for effect. Before using drug combinations, the product literature of the other products should be reviewed.


Intramuscular injection.

  • For moderate-deep sedation and restraint of cats, the product should be administered at a dose of 50 – 150 µg medetomidine hydrochloride /kg body weight (corresponding to 0.05 – 0.15 ml Cepetor / kg body weight).
  • For anaesthesia, the product should be administered at a dose of 80 µg medetomidine hydrochloride/kg body weight (corresponding to 0.08 ml Cepetor/kg body weight) and 2.5 to 7.5 mg ketamine/kg body weight. At this dose, anesthesia occurs within 3 – 4 minutes and lasts for 20 – 50 minutes. For procedures that last longer, the administration should be repeated by administering half the initial dose (i.e. 40 µg medetomidine hydrochloride (corresponding to 0.04 ml Cepetor/kg body weight) and 2.5 – 3.75 mg ketamine/kg body weight) or just 3.0 mg ketamine/kg body weight. Alternatively, for longer lasting procedures, anesthesia can be prolonged by administering the inhalation anesthetics isoflurane or halothane, with oxygen or oxygen/nitrous oxide.


One ml contains:

Medetomidine Hydrochloride 1 mg

Cepetor 1 mg/ml is available in a 10 ml vial.

Side effects

Dogs and cats:

Bradycardia with atrial ventricular block (first and second degree) and extrasystole from time to time. Vasoconstriction of the coronary artery. Decreased cardiac output. Blood pressure will first increase after administration and then return to normal blood pressure, or a slightly lower blood pressure. Some dogs and most cats will vomit within 5-10 minutes of injection. Cats may also vomit during the recovery period. Hypersensitivity to loud noises has been observed in a few individuals. Increased diuresis. Hypothermia. mydriasis. In rare cases, pulmonary edema has been observed. Respiratory depression, cyanosis, injection site pain and muscle tremor may occur. In individual cases reversible hyperglycemia due to suppression of insulin secretion.

In cases of circulatory and respiratory depression, manual ventilation and oxygenation may be indicated. Atropine can increase the heart rate. The above side effects may be more common in dogs weighing less than 10 kg.

If you notice any serious side effects or other reactions not mentioned in this leaflet, please inform your veterinarian.


Download the leaflet.

Download PDF